Telomir Pharmaceuticals, Inc.

TELO · Nasdaq · SIC 2834: Pharmaceutical Preparations
68
SEC Filings

Business Summary

PART I ITEM 1. Description of Business Overview Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. Our research strategy targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mit...

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTELOdiscussed_in_filing Artificial Intelligence
topic_mentionTELOdiscussed_in_filing Cybersecurity
topic_mentionTELOdiscussed_in_filing Trusted Computing
topic_mentionTELOdiscussed_in_filing Blockchain & Crypto
topic_mentionTELOdiscussed_in_filing Regulation
topic_mentionTELOdiscussed_in_filing Automotive
topic_mentionTELOdiscussed_in_filing Healthcare & Bio
topic_mentionTELOdiscussed_in_filing Platform & Ecosystem
topic_mentionTELOdiscussed_in_filing Networking
topic_mentionTELOdiscussed_in_filing Artificial Intelligence
topic_mentionTELOdiscussed_in_filing Cybersecurity
topic_mentionTELOdiscussed_in_filing Trusted Computing
topic_mentionTELOdiscussed_in_filing Blockchain & Crypto
topic_mentionTELOdiscussed_in_filing Regulation
topic_mentionTELOdiscussed_in_filing Automotive
topic_mentionTELOdiscussed_in_filing Healthcare & Bio
topic_mentionTELOdiscussed_in_filing Platform & Ecosystem
topic_mentionTELOdiscussed_in_filing Networking
topic_mentionTELOdiscussed_in_filing Artificial Intelligence
topic_mentionTELOdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-172025-12-310001493152-26-010625EDGAR51K words
2025-02-042024-12-310001493152-25-004872EDGAR—
2024-03-292023-12-310001493152-24-012049EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001493152-25-021496EDGAR15K words
2025-08-142025-06-300001641172-25-023970EDGAR—
2025-05-142025-03-310001641172-25-010298EDGAR—
2024-11-122024-09-300001493152-24-044749EDGAR—
2024-08-132024-06-300001493152-24-031606EDGAR—
2024-05-132024-03-310001493152-24-018909EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001493152-26-013872EDGAR0K words
2026-03-310001493152-26-013785EDGAR—
2026-03-270001493152-26-013240EDGAR—
2026-02-170001493152-26-006937EDGAR—
2026-02-050001493152-26-005199EDGAR—
2026-01-120001493152-26-001170EDGAR—
2026-01-050001493152-26-000267EDGAR—
2025-12-220001493152-25-028620EDGAR—
2025-12-170001493152-25-028126EDGAR—
2025-11-240001493152-25-024818EDGAR—

68 total filings indexed. 49 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001971532
TickerTELO
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedFL

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 0ded1737935345264edb188962afbd3a152e3a452f4b2aaf1c358f8b8da2e617
parent: c831819fff90784db66474a34a8cf7a1f9a5fe2599ec5e21e36606e932d68d7f
content hash: 4e0a263f858598fe84e2bf4cdf008c680dfedeb79c6c60ac7cd8b79ecee8dd21
signed: 2026-04-13T04:47:45.942Z
sources: 9 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf